Perry Cook, M.D.

Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
Cornely, Oliver A; Aversa, Franco; Cook, Perry; Jones, Brian; Michallet, Mauricette; Shea, Thomas; Vallejo, Carlos
2011 Oct;87(4):289-301, European journal of haematology
Invasive fungal infection (IFI) is a persistent problem among critically ill and immunocompromised patients, especially hematopoietic stem cell transplant or solid organ transplant recipients, or patients on intensive chemotherapy for acute leukemia. Although numerous antifungal agents are available, IFI remains a serious problem because of obstacles to timely diagnosis and high morbidity and mortality rates associated with such infection. Improvements in treatment of underlying diseases have rapidly expanded the patient populations at risk for IFI with increased use of immunosuppressants, aggressive chemotherapy, broad-spectrum antibiotics, and narrow-spectrum antifungal prophylaxis. There are various treatment strategies that can be used to manage IFI: prophylaxis, empiric, preemptive, and directed. As the infection progresses, the prospect of successfully treating an infection diminishes; conversely, the earlier the intervention, the greater the possibility of unnecessary treatment. This article discusses the epidemiology of the most important fungal pathogens, identifies high-risk patient groups and risk factors associated with IFI, and critically evaluates the advantages and disadvantages of available diagnostic tests and treatment strategies and the rationale for antifungal prophylaxis. For patients at high risk for IFI, antifungal prophylaxis is an attractive strategy, and numerous randomized, controlled clinical studies have documented the benefit of such prophylaxis as well as the most efficacious of currently available agents
— id: 140029, year: 2011, vol: 87, page: 289, stat: Journal Article,

Multiple myeloma involving skin and pulmonary parenchyma after autologous stem cell transplantation
Yuan, Yuan; Wieczorek, Rosemary; Green, David L; Cook, Perry; Ballard, Harold; Araten, David J
2009 ;2:48-48, Journal of hematology & oncology
ABSTRACT: Pulmonary involvement and skin involvement are rare complications of plasma cell neoplasms. Here we describe what may be the first reported case of a patient with relapse in both of these sites following autologous peripheral blood stem cell transplantation
— id: 105651, year: 2009, vol: 2, page: 48, stat: Journal Article,

Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells
Burger, Patricia E; Coetzee, Sandra; McKeehan, Wallace L; Kan, Mikio; Cook, Perry; Fan, Yong; Suda, Toshio; Hebbel, Robert P; Novitzky, Nicolas; Muller, William A; Wilson, E Lynette
2002 Nov 15;100(10):3527-3535, Blood
Recent experiments show that hematopoietic progenitor cell populations contain endothelial precursor cells. We have isolated a population of CD34(+) cells that expresses fibroblast growth factor receptor-1 (FGFR-1) and that differentiates into endothelial cells in vitro. We find that 4.5% +/- 2.1% of CD34(+) cells isolated from bone marrow, cord blood, and mobilized peripheral blood express FGFR-1 and that viable CD34(+)FGFR(+) cells are small, with little granularity, and express both primitive hematopoietic and endothelial markers on their surface. The primitive hematopoietic markers AC133, c-kit, and Thy-1 are coexpressed by 75%, 85%, and 64% of CD34(+)FGFR(+) cells, respectively. Most of the CD34(+)FGFR(+) cells also express antigens found on endothelial cells, such as CD31, vascular endothelial growth factor receptor-2, and the endothelial-specific cell surface marker, vascular endothelial cadherin (VE-cadherin), whereas 56% to 60% of the cells express Tie, Tek, and the endothelial-specific marker, P1H12. The CD34(+)FGFR(+) population is enriched in cells expressing endothelial-specific antigens compared with the CD34(+) population. Isolated CD34(+)FGFR(+) cells grow slowly in culture, are stimulated by fibroblast growth factor-2 and vascular endothelial growth factor, and give rise to cells that express von Willebrand factor and VE-cadherin and that incorporate acetylated low-density lipoprotein. These experiments show that FGFR-1 is expressed by a subpopulation of CD34(+) cells that give rise to endothelial cells in vitro, indicating that this population contains endothelial stem/progenitor cells
— id: 35190, year: 2002, vol: 100, page: 3527, stat: Journal Article,

Classifying chronic myelomonocytic leukemia
Yavorkovsky, LL; Cook, P
2001 SEP 1 ;19(17):3790-3791, Journal of clinical oncology
— id: 54939, year: 2001, vol: 19, page: 3790, stat: Journal Article,

Monocytic leukemia cutis diagnosed simultaneously with refractory anemia with monocytosis: A case report
Yavorkovsky, LL; Zain, J; Wu, CD; Trivelli, L; Cook, P
2001 FEB ;66(2):120-122, American journal of hematology
A case of leukemia cutis (LC) of monocytic lineage in a patient with myelodysplastic syndrome (MDS) is presented. Cutaneous infiltrates were recognized concurrent with diagnosis of refractory anemia (RA) with monocytosis. Skin infiltrates subsequently spontaneously regressed although MDS progressed with increasing monocytosis, anemia, and thrombocytopenia, Death occurred 6 months after diagnosis with evolution of acute monoblastic leukemia complicated by sepsis, This case supports previous observations of poor prognosis associated with leukemia cutis, LC associated with MDS is reviewed including the role of monocytes. (C) 2001 Wiley-Liss, Inc
— id: 55239, year: 2001, vol: 66, page: 120, stat: Journal Article,

First case report of bartonella henselae bacteremia in autologous peripheral stem cell transplantation
Niazi, MA; Zain, J; Takeshita, K; Tierno, PM; Cook, P
2000 NOV 16 ;96(11):342B-342B, Blood
— id: 55224, year: 2000, vol: 96, page: 342B, stat: Journal Article,

Acquired von Willebrand's disease (AvWD) diagnosed concurrently with T cell (CD3+, CD4+) lymphoproliferative disorder: A case report
Yavorkovsky, LL; Singareddy, S; Holkova, B; Nardi, M; Cook, P
2000 NOV 16 ;96(11):233B-233B, Blood
— id: 55222, year: 2000, vol: 96, page: 233B, stat: Journal Article,

Endothelial and primitive hematopoietic cell surface markers are co-expressed on a CD34+population that expresses fibroblast growth factor receptors (FGFRs)
Burger, PE; Coetzee, S; Salm, S; Cook, P; Fan, Y; McKeehan, WL; Kan, M; Suda, T; Hebbel, RP; Novitsky, N; Wilson, EL
1999 NOV 15 ;94(10):464A-464A, Blood
— id: 54779, year: 1999, vol: 94, page: 464A, stat: Journal Article,

Second autologous transplantation for relapse of non Hodgkin's lymphoma (NHL): Better result with an alternative preparative regimen; A case report
Chanan-Khan, A; Dentchev, T; Cook, P
1999 NOV 15 ;94(10):398B-398B, Blood
— id: 54783, year: 1999, vol: 94, page: 398B, stat: Journal Article,

Laparoscopy in 533 patients with abdominal malignancy
Pearlstone, D B; Mansfield, P F; Curley, S A; Kumparatana, M; Cook, P; Feig, B W
1999 Jan;125(1):67-72, Surgery
BACKGROUND: Laparoscopy in patients with intra-abdominal malignancy remains controversial. This study evaluates the incidence of tumor recurrence at the port site after laparoscopy in patients with intra-abdominal malignancy. METHODS: The medical records of all patients with nongynecologic malignancies who underwent laparoscopic procedures between May 1, 1990, and June 30, 1996, at the University of Texas M.D. Anderson Cancer Center were reviewed. Data on extent of tumor, histologic findings, primary location, procedures performed, and complications were recorded. RESULTS: During this time, 533 patients with known intra-abdominal malignancies underwent laparoscopy. Mean follow-up time was 13.2 +/- 0.5 months (range 1 to 71 months; median 10.6 months). Four recurrences at the port site were identified (0.8%). Three of these patients had advanced intra-abdominal disease at the time of laparoscopy; 1 patient without advanced disease at the time of laparoscopy had a recurrence at the port site as the only site of recurrent disease (0.19%). The incidence of port site recurrences among patients with advanced intra-abdominal disease at the time of laparoscopy (3/71) was significantly greater than the risk of development of a recurrence at the port site among patients without advanced intra-abdominal disease at the time of laparoscopy (1/462; P < .0003, by chi-square analysis). CONCLUSION: Recurrence at the port site is very rare. When implantation at the port site does occur, it is most commonly associated with advanced intra-abdominal disease
— id: 133395, year: 1999, vol: 125, page: 67, stat: Journal Article,

Isolation and characterization of a CD34+ population that expresses fibroblast growth factor receptors
Burger, PE; Coetzee, S; Cook, P; Fan, Y; McKeehan, WL; Kan, M; Suda, T; Mansveldt, E; Novitsky, N; Wilson, EL
1998 NOV 15 ;92(10):56A-56A, Blood
— id: 53626, year: 1998, vol: 92, page: 56A, stat: Journal Article,

Feasibility of high dose busulfan and melphalan with autologous hematopoietic stem cell transplantation in multiple myeloma
Begum, U; Fitzgerald, D; Yong, LO; Grand, M; Thomas, U; Chen, Y; Patel, A; Goodman, D; Dillon, C; Amorosi, E; Cook, P
1997 NOV 15 ;90(10):4346-4346, Blood
— id: 53139, year: 1997, vol: 90, page: 4346, stat: Journal Article,

Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study
Hochberg, F; Prados, M; Russell, C; Weissman, D; Evans, R; Cook, P; Burton, G; Eisenberg, PD; Valenzuela, R; Verkh, L
1997 MAR ;32(1):45-55, Journal of neuro-oncology
Objectives: To evaluate the toxicity and response rate following BCNU with oxygen inhalation and escalating dosages of fluosol administered to patients with radiographic progression of malignant glioma after definitive surgery and radiotherapy. Method: This single arm, phase I-II multicenter trial, enrolled 99 patients with malignant gliomas recurrent after definitive surgery and radiotherapy. All patients received a fixed dose (200 mg/m(2)) of BCNU along with 100% oxygen and fluosol, a perfluorochemical. Fluosol doses were escalated between patients (150, 275, 400 and 600 ml/m(2)). Treatment was repeated every 6 weeks for a maximum of 6 cycles. Patients were assessed for toxicity at the time of infusion and sequentially thereafter. Response was evaluated clinically and radiologically at least every 6 weeks. Results: Treatment was well tolerated. Dose reductions were required at least once in 18 patients, treatment delays were necessary at least once in 33 patients. Grade 3-4 leukopenia occurred in 6 patients (12 events), grade 3-4 thrombocytopenia in 10 patients (25 events) and grade 3-4 liver enzymes elevations in 18 patients (31 events). Higher fluosol dosages did not produce increases in toxicity or responses. Response or stabilization was seen in 57% (38% were stabilizations) of the patients who entered the trial with progressive disease. The median time to progression was 45 weeks, and median survival was 66 weeks for patients who had response or stabilization. For patients with glioblastoma response/stabilization was seen in 45% with a mean duration of 24 weeks, for patients with anaplastic astrocytoma response/stabilization was seen in 68 % with a mean duration of 50 weeks. Conclusion: This treatment regimen is well tolerated. Our results suggest fluosol may enhance the effectiveness of BCNU for the treatment of recurrent malignant gliomas. Future studies will be performed using fluosol at the dose of 400 ml/m(2)
— id: 53284, year: 1997, vol: 32, page: 45, stat: Journal Article,

Transfer of human adenine deaminase gene into murine hematopoietic stem cells: sequential study of spleen colony-forming units from bone marrow of living mice and the requirement of the microenvironment
Cook PC; Jiang S; Chertkov JL; Fan Y; Levere RD; Abraham NG
1996 ;96(2):57-63, Acta haematologica
Irradiated female mice were reconstituted with male hematopoietic stem cells (HSCs) retrovirally marked with human adenine deaminase (hADA) complimentary DNA. HSCs were incubated with interleukin-6 and stem cell factor before coculture with GP+E86-producing cells. Bone marrow HSCs were infused intravenously to irradiated mice and spleen colony-forming units (CFU-S) were evaluated for hADA marked clones by Southern blot analysis. 45 of 54 CFU-S were marked by the hADA gene sequence with multiple copies integrated per genome. Oligoclonal hematopoiesis evolved over time with 1-2 clones demonstrated 5-11 months after reconstitution. Comparable results were obtained with embryonic fetal liver HSCs. Incubation of bone marrow HSCs with adherent stromal cells rather than growth factors produced less efficient gene transfer, and polyclonal hematopoiesis was not observed. Donor origin was established by the Y chromosome probe. These results support the clonal succession model of hematopoiesis
— id: 12692, year: 1996, vol: 96, page: 57, stat: Journal Article,